To demonstrate the applicability of our protocol in a pharmaceutically relevant scenario, we tested its capability to generate compounds that have similar binding and structural features to known inhibitors of the protein kinase CK1δ, a protein that is involved in several neurodegenerative diseases, such as AD, PD, and ALS. Here, WEE1 is linked to amyotrophic lateral sclerosis.